Get the Stockscreener App
1.02
1.92%
-0.02
Renovorx Inc stock is traded at $1.02, with a volume of 1,010.
It is down -1.92% in the last 24 hours and up +0.00% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$1.04
Open:
$1.02
24h Volume:
1,010
Relative Volume:
0.03
Market Cap:
$25.19M
Revenue:
-
Net Income/Loss:
$-10.23M
P/E Ratio:
-0.9714
EPS:
-1.05
Net Cash Flow:
$-10.26M
1W Performance:
-1.38%
1M Performance:
+0.00%
6M Performance:
-16.39%
1Y Performance:
-11.30%
1-Day Range:
$1.02
$1.05
1-Week Range:
$0.90
$1.05
52-Week Range:
$0.5306
$2.35
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
333 W. SANTA CLARA STREET, SUITE 900, SAN JOSE
Renovorx Inc Stock (RNXT) Latest News
We Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully - Simply Wall St
RenovoRx (NASDAQ:RNXT) Stock Price Up 2.5% – Still a Buy? - Defense World
RenovoRx ramps up production of RenovoCath system By Investing.com - Investing.com Australia
RenovoRx ramps up production of RenovoCath system - Investing.com
RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians - GlobeNewswire
Rhumbline Advisers Has $1.23 Million Stock Holdings in The RMR Group Inc. (NASDAQ:RMR) - Defense World
Renovos Biologics Appoints New Non-Executive Director - European Pharmaceutical Manufacturer
RXO Inc (RXO) Shares Up 4.51% on Sep 19 - GuruFocus.com
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer - StockTitan
State of New Jersey Common Pension Fund D Has $2.48 Million Stock Position in RXO, Inc. (NYSE:RXO) - Defense World
Jefferies initates Ralph Lauren Corp (RL) stock to a Buy - Knox Daily
Reckitt shares up on report of potential homecare asset sale By Investing.com - Investing.com Australia
Reckitt starts talks on $7.9 bln homecare assets sale, Bloomberg News reports - XM
Federated Hermes Inc. Boosts Stock Position in The RMR Group Inc. (NASDAQ:RMR) - Defense World
Ascendiant Capital Markets Increases RenovoRx (NASDAQ:RNXT) Price Target to $8.25 - Defense World
RenovoRx (NASDAQ:RNXT) Trading Up 1.7% - Defense World
What was RenovoRx Inc (RNXT)’s performance in the last session? - US Post News
The time has not yet come to remove your chips from the table: RenovoRx Inc (RNXT) - SETE News
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 26th Annual Global Investment Conference on September 9, 2024 in New York - StockTitan
RNXT Stock Earnings: RenovoRx Meets EPS for Q2 2024 - MSN
RenovoRx (NASDAQ:RNXT) Releases Quarterly Earnings Results - Defense World
RenovoRx continues drug-device combo Phase III trial in pancreatic cancer - Yahoo Finance
RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial - StockTitan
RenovoRx, Inc. - Stocks Telegraph
TAMP therapy shows promise in pancreatic cancer survival By Investing.com - Investing.com Nigeria
TAMP therapy shows promise in pancreatic cancer survival - Investing.com
RenovoRx Announces Publication of Positive Early-Stage Clinical Data in International Peer-Reviewed Journal, The Oncologist® - StockTitan
UNMC joins trial exploring new pancreatic cancer treatment - University of Nebraska Medical Center
Nektar Therapeutics (NASDAQ:NKTR) vs. RenovoRx (NASDAQ:RNXT) Critical Comparison - Defense World
RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist® - StockTitan
RenovoRx Announces Publication Of Results Of Pre-Clinical Studies Support Efficacy And Drug Delivery Mechanism ... - Quantisnow
RenovoRx CEO Updates Shareholder Letter - Quantisnow
University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC ... - StockTitan
RenovoRx Inc (RNXT) deserves closer scrutiny – US Post News - US Post News
RenovoRx (NASDAQ:RNXT) Coverage Initiated by Analysts at Ascendiant Capital Markets - Defense World
Ascendiant Capital highlights cancer therapy, sees potential on RenovoRx stock - Investing.com India
Ascendiant Capital highlights cancer therapy, sees potential on RenovoRx stock By Investing.com - Investing.com Australia
Analyzing Verrica Pharmaceuticals (NASDAQ:VRCA) and RenovoRx (NASDAQ:RNXT) - Defense World
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Benzinga
RenovoRx appoints new SVP to bolster strategy By Investing.com - Investing.com
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships - StockTitan
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships - GlobeNewswire Inc.
RenovoRx appoints new SVP to bolster strategy - Investing.com India
RenovoRx announces $5M registered direct offering priced at-the-marketTipRanks.com - TipRanks
RenovoRx, Inc. (NASDAQ:RNXT) Short Interest Up 28.9% in May - Defense World
RenovoRx (RNXT) Stock Price, News & Analysis - MarketBeat
RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers - Quantisnow
RenovoRx raises $17.2 million to advance cancer trialInvesting.com ZA - Investing.com South Africa
RenovoRx raises $17.2 million to advance cancer trial By Investing.com - Investing.com
RenovoRx CEO Issues Update Letter to Shareholders - Business Wire
Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's ... - Chronicle-Tribune
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):